These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24534802)

  • 1. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
    Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
    Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
    J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
    J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
    J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
    Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
    Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
    Pivot X; Suter T; Nabholtz JM; Pierga JY; Espie M; Lortholary A; Khayat D; Pauporte I; Romieu G; Kramar A; Fumoleau P
    Eur J Cancer; 2015 Sep; 51(13):1660-6. PubMed ID: 26163096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients.
    Dores H; Abecasis J; Correia MJ; Gândara F; Fonseca C; Azevedo J; Arroja I; Martins A; Mendes M
    Arq Bras Cardiol; 2013 Apr; 100(4):328-32. PubMed ID: 23525273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population.
    Baron KB; Brown JR; Heiss BL; Marshall J; Tait N; Tkaczuk KH; Gottlieb SS
    J Card Fail; 2014 Aug; 20(8):555-9. PubMed ID: 24905295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
    Sawaki M; Mukai H; Tokudome N; Nakayama T; Taira N; Mizuno T; Yamamoto Y; Horio A; Watanabe T; Uemura Y; Ohashi Y
    Breast Cancer; 2012 Jul; 19(3):253-8. PubMed ID: 21526424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
    J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
    Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
    Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
    Morris PG; Iyengar NM; Patil S; Chen C; Abbruzzi A; Lehman R; Steingart R; Oeffinger KC; Lin N; Moy B; Come SE; Winer EP; Norton L; Hudis CA; Dang CT
    Cancer; 2013 Nov; 119(22):3943-51. PubMed ID: 24037735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
    Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
    Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
    Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
    Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population.
    Adamo V; Ricciardi GR; Adamo B; Ferraro G; Franchina T; Rossello R; Zanghì M; Cicero G; Rizzo S; Caristi N; Russo A
    Oncology; 2014; 86(1):16-21. PubMed ID: 24335608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.